ReviewJournal of clinical medicine2020
COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 6 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis.Digestive diseases and sciences · 2023Pooled it
- Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Elevated De Ritis Ratio Is Associated With Poor Prognosis in COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Is liver involvement overestimated in COVID-19 patients? A meta-analysis.International journal of medical sciences · 2021Pooled it
- Short- and potential long-term adverse health outcomes of COVID-19: a rapid review.Emerging microbes & infections · 2020Pooled it
- Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19.Alimentary pharmacology & therapeutics · 2020Pooled it
- COVID-19 Infection, Drugs, and Liver Injury.Journal of clinical medicine · 2025Review
- Liver Enzymes Changes and their Association with Outcome in Hospital Inpatients with COVID-19 in Jordan.Middle East journal of digestive diseases · 2025Article
- Characteristics and mechanisms of liver injury caused by emerging infectious diseases.Frontiers in immunology · 2025Review
- The effect of SARS-CoV-2 infection on the liver function tests: a systematic review and meta-analysis of observational studies.Przeglad gastroenterologiczny · 2025Review
- IGSF1: a biomarker for predicting prognosis, immunotherapy response, and drug candidates in COVID-19 combined hepatocellular carcinoma.Discover oncology · 2024Article
- Assessment of the liver with two-dimensional shear wave elastography following COVID-19 infection: A pilot study.Australasian journal of ultrasound in medicine · 2024Article
- Spectrum of COVID-19 induced liver injury: A review report.World journal of hepatology · 2024Review
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- Review
- The plasma metabolome of long COVID patients two years after infection.Scientific reports · 2023Article
- Comprehensive DNA methylation profiling of COVID-19 and hepatocellular carcinoma to identify common pathogenesis and potential therapeutic targets.Clinical epigenetics · 2023Article
- COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations.World journal of hepatology · 2023Review
- The impact of COVID-19 on liver injury in various age.World journal of virology · 2023Review
- Acute-on-chronic liver failure in patients with severe acute respiratory syndrome coronavirus 2 infection.World journal of hepatology · 2023Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.